Fatality Rate and Survival Time of Laboratory-Confirmed COVID-19 for Patients in England During the First Wave of SARS-CoV-2 Infection: A Modelling Study.
covid-19
fatality rate
joinpoint
modelling
mortality rate
sars-cov-2
survival time
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
accepted:
20
07
2021
entrez:
13
9
2021
pubmed:
14
9
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Background Fatality rate estimates for coronavirus disease 2019 (COVID-19) have varied widely. A major confounding factor in fatality rate estimates is the survival time (time from diagnosis to death). Predictive models that incorporate the survival time benefit from greater accuracy due to the elimination of sampling bias. This study outlines a survival time-based predictive model that estimates a precise fatality rate for patients with laboratory-confirmed COVID-19. This model was utilised to predict deaths for COVID-19 patients who died during the first wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in England. Methodology This study included Public Health England (PHE) data for cumulative laboratory-confirmed COVID-19 cases (n = 143,463) and deaths (n = 30,028) that were reported by PHE between 30 January and 14 May 2020 in England, that is, from the first COVID-19 case in England and the most recently available data at the time of conducting this study. Fatality rate and survival time were estimated by linear regression analysis. This enabled the predicted cumulative COVID-19 deaths to be calculated up to 21 May 2020. Time periods with significantly different rates in daily deaths were identified using Joinpoint trend analysis. Results A fatality rate of 21.9% (95% confidence interval = 21.8% to 22.0%) with a survival time of seven days was determined for patients in England with laboratory-confirmed COVID-19 during the first wave of SARS-CoV-2 infection. Based on these estimates, predicted trends for cumulative and daily laboratory-confirmed COVID-19 deaths were generated with >99% and >96% accuracy with reported data, respectively. This model predicted that the number of cumulative laboratory-confirmed COVID-19 deaths in England was likely to be 31,420 by 21 May 2020. Joinpoint trend analysis identified significant differences in predicted daily laboratory-confirmed COVID-19 deaths during the following periods: 10.5 (6 to 17 March), 111.0 (17 to 27 March), 446.8 (27 March to 4 April), 817.0 (4 to 23 April), 536.3 (23 April to 7 May), and 266.7 (7 to 21 May) daily deaths (P < 0.001). Conclusions During the first wave of SARS-CoV-2 infection in England, the fatality rate of laboratory-confirmed COVID-19 was 21.9%. The survival time of these patients was seven days. The predictive model presented in this study can be adapted for estimating COVID-19 deaths in different geographical regions. As such, this study has utility for clinicians, scientists, and policymakers responding to new waves of SARS-CoV-2 infection because the methodology can be applied to more recent time periods as new data for COVID-19 cases and deaths become available.
Identifiants
pubmed: 34513472
doi: 10.7759/cureus.16899
pmc: PMC8412062
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e16899Informations de copyright
Copyright © 2021, Hillyar et al.
Déclaration de conflit d'intérêts
The authors have declared financial relationships, which are detailed in the next section.
Références
Clin Chem. 2020 Jun 1;66(6):794-801
pubmed: 32246822
Clin Infect Dis. 2020 Jul 28;71(15):863-865
pubmed: 32232322
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
J Korean Med Sci. 2020 Mar 30;35(12):e132
pubmed: 32233161
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Euro Surveill. 2020 Mar;25(12):
pubmed: 32234121
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Early Hum Dev. 2020 May;144:105026
pubmed: 32247898
Lancet Glob Health. 2020 Apr;8(4):e480
pubmed: 32109372
Int J Antimicrob Agents. 2020 Apr;55(4):105946
pubmed: 32199877
J Med Virol. 2020 Oct;92(10):1755-1756
pubmed: 32270882
Disaster Med Public Health Prep. 2020 Jun;14(3):384-386
pubmed: 32228738
J Med Virol. 2020 Jul;92(7):903-908
pubmed: 32219885
Clin Med (Lond). 2020 Mar;20(2):124-127
pubmed: 32139372